LONDON, GREATER LONDON, UNITED KINGDOM, September 10, 2025 / EINPresswire.com / -- What Is The Cellular Tumor Antigen p53 Market Size And Growth?

Researchers at Moffitt Cancer Center have created the first genetically engineered model of lung cancer in naked mole rats, a ...

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...

In a groundbreaking review published in Current Molecular Pharmacology, a team led by Dr. Jhi Biau Foo from Taylor’s University unveils the pivotal role of mutant p53 (mutp53) in driving cancer ...

The firm said it will enroll more ovarian cancer patients in its ongoing Phase II trial to gather data for a regulatory submission for rezatapopt to the FDA.

PMV Pharmaceuticals Inc.’s rezatapopt yielded impressive overall response data in ovarian cancer, prompting the firm to aim ...

Dr Deepika Jalota, Chief Development Officer, said: “These phase 2 PYNNACLE interim trial data illustrate that rezatapopt, a ...

PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.

Researchers at Moffitt Cancer Center have created the first genetically engineered model of lung cancer in naked mole rats, a species long thought to be resistant to cancer. The findings, published in ...